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RESULTS: The percentage of successful intercourse with
Viagra treatment was 72% while with the Muse treat-
ment, it was 63%. The incremental cost-effectiveness ra-
tio was calculated to be $628 per successful intercourse. 
CONCLUSION: Our results indicate that one additional
successful intercourse would cost $628 more when switch-
ing from Muse to Viagra. If using an average cut-off ratio
of $50 per successful event which was estimated directly
from a group of patients’ preferences as a willingness-to-
pay measure, we concluded that Viagra could not be con-
sidered to be cost-effective compared to Muse in the
treatment of male erectile dysfunction.
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ECONOMIC EVALUATION IN REAL-LIFE 
SETTING OF ALPHA-BLOCKERS VERSUS 
FINASTERIDE VERSUS SERENOA REPENS
IN THE TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA
Schmitt C1, Aussage P1, Berdeaux G2
1ARCOS, Issy-les-Moulineaux, France; 2Pierre Fabre 
Médicament, Boulogne-Billancourt, France
OBJECTIVE: To identify prescription patterns and costs
of benign prostatic hyperplasia (BPH) therapy in a real-
life setting. 
METHODS: Records from the French primary care data-
base Thales were screened to identify patients who initi-
ated a therapy with either -blockers (A) [alfuzosin, tam-
sulosin, terazosin] or finasteride (F), or a lipido-sterolic
extract of Serenoa repens (Px), between June 1996 and
May 1997 and who were followed up for at least 12
months. Patients with a diagnosis of prostatic cancer were
excluded. Endpoints were: 1-year BPH related costs, con-
comitant medication costs and total healthcare costs ac-
cording to the French National Health System. In order
to adjust for differences of socioeconomic and clinical
characteristics between treatment groups, endpoints were
analyzed using the propensity score method. 
RESULTS: 601 patients were identified in group A, 264 in
group F, and 315 in group Px. The median age was 67
years. Groups were unbalanced as to age (P  0.01), hy-
pertension (P  0.05), and urological troubles (P  0.05):
A were prescribed to younger patients with less hyperten-
sion, while F was prescribed to patients with less urologi-
cal disturbances. Unadjusted annual total healthcare costs
per patient were $1130 for group A, $1360 for group F,
and $1120 for group Px. Difference between A and Px re-
mained after adjustment ($36), due to a lower price of Px
and to reduced concomitant prescription costs. Difference
between F and Px also remained after adjustment ($242),
due to the previous reasons but also to a shorter treatment
duration. 
CONCLUSION: In real-life clinical practice, annual total
healthcare costs were lower when initiating a treatment
for BPH with Serenoa repens than with finasteride and
-blockers.
USE OF OUTCOMES RESEARCH (ECONOMIC, 
CLINICAL, HUMANISTIC) IN HEALTHCARE 
DECISION-MAKING
PPO1
THE ROLE OF QUALITY OF LIFE INFORMATION 
IN MANAGED CARE DECISION-MAKING
Crawford B1, Dukes E2, Bailey L3, Evans C1
1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, 
Chesterbrook, PA, USA; 3MAPI Values, Bollington, UK
The role of quality of life information in influencing man-
aged care decision-making in the United States is not well
understood. Previous research has suggested that efficacy,
safety, and cost-effectiveness information is viewed with
the highest level of importance and quality of life informa-
tion is viewed as more supplemental in nature. 
OBJECTIVE: The purpose of this study was to gain an
understanding of how decision-makers view quality of
life information. In particular, 1) the current and future
use of the information was examined, 2) the usefulness
and understanding of several types of QoL instruments,
and 3) the perceived weaknesses and strengths of quality
of life research. 
METHODS: Forty-one pharmacy and managed care di-
rectors completed a questionnaire by telephone to elicit
their attitudes on QoL research in managed care deci-
sion-making. 
RESULTS: Respondents felt that disease-specific quality of
life instruments were most useful (mean rank of 1.90 on a
5-point scale; 1  most useful), patient utility measures
ranked 3.10 and generic quality of life measures 3.83. Re-
spondents were asked their level of familiarity (5-point
Likert scale) with 11 common, disease-specific and generic
measures. They were most familiar with the SF-36 (mean
rank 3.17) and least familiar with the EuroQoL (mean
rank 1.34). Respondents felt that the results of QoL evalu-
ations could not be generalized (51.2%) and suffered from
too many assumptions (53.7%). Most respondents (52.7%)
felt that the main strength of QoL studies was that they
consider the perspective of the patient. 
CONCLUSIONS: Familiarity with QoL research and in-
struments by MCO decision-makers is relatively low, and
research in the area suffers from broad acceptability. Fu-
ture work should be conducted to educate MCOs on the
usefulness of QoL evaluations.
PPO2
THE DEVELOPMENT OF A PRACTICAL 
PROVIDER PROFILING REPORT
Gevirtz F, Nash DB, Moxey ED, O’Connor JP, Turk B, 
Corrato R
Office of Health Policy and Clinical Outcomes, Philadelphia, 
PA, USA
Healthcare providers are under increasing pressure to doc-
ument their outcomes to managed care organizations, em-
Abstracts 213
ployers and consumers. Performance measurement has be-
come an important tool to demonstrate the value of disease
state management and provider performance improvement
programs. Providing feedback to physicians in the form of
performance reports with appropriate benchmarks in-
creases the likelihood of physician improvement. 
OBJECTIVE: The purpose of this project was to develop
a simple and practical tool to evaluate performance of in-
dividual physicians and clinics in a large physician prac-
tice management organization. 
METHODS: Clinical, economic (RVUs), and relational
outcomes were summarized and trended over time. Clini-
cal outcomes examined both general and disease-specific
(diabetes and asthma) endpoints. Relational outcomes in-
cluded patient reported disease-specific satisfaction, qual-
ity of life, and educational initiatives. Disease-specific
clinical outcomes were compared to nationally developed
and accepted practice guidelines. An extensive literature
review on profiling and risk adjustment was also con-
ducted to help develop format and layout of the profiles. 
RESULTS: Several informative, easy-to-read reports were
developed to measure provider/disease-specific clinical
outcomes, provider/disease-specific satisfaction, and pro-
vider-specific economic outcomes. Provider profiles were
actionable, derived from practice guidelines, minimally
intrusive, and relevant. The profiles measured the perfor-
mance of each provider against the overall performance
of his/her clinic and against the physician practice man-
agement organization. 
CONCLUSION: The development of provider profiles
that summarize the critical elements essential for managing
patient care is a practical way to evaluate provider perfor-
mance against nationally recognized standards with mini-
mal data collection burden. Profiles can provide valuable
information to physicians about their own performance,
as well as to managed care organizations and consumers
interested in provider-specific outcome measures.
PPO3
DESIGNING A USER-FRIENDLY OUTCOMES 
RESEARCH DATABASE FOR THE PRIVATE 
MEDICAL PRACTITIONER
Sarpong DF
Xavier University College of Pharmacy, New Orleans, LA, USA
The goal of healthcare service is to optimize biologic
function and postpone the inevitable physical decline of
the patient. This service is characterized by quality, effec-
tiveness, and cost efficiency. To achieve this end, practi-
tioners and other parties in the health industry must be
continuously involved in gathering and evaluating assess-
ment data, given that outcomes assessment is a data-
driven process which quantifies the quality and effective-
ness of the healthcare received by the patient. Besides
methodological challenges faced by practitioners, the
lack of user-friendly and cost-effective data management
system posses great barrier to particularly the private
practitioner. 
OBJECTIVE: The primary objective of this research
project was to design a user-friendly and cost-effective
database system that will afford private medical (health)
practitioners the opportunity to be active participants in
outcomes research and pharmacoeconomics/health eco-
nomics. 
METHOD: The main database system was designed using
Microsoft ACCESS software. Microsoft ACCESS was the
choice because 1) it interfaces with a number database/
spreadsheet programs, and 2) it affords the user the oppor-
tunity to create distributable, royal-free, stand-alone appli-
cations. The data-entry form (an interface) was designed
using Visual Basic, an object-oriented language, given that
the user can write efficient and polished programs every
bit as professional as commercial applications. 
RESULTS: The database was user-friendly and has capa-
bilities such the practitioner can: 1) evaluate each pa-
tient’s response to treatment over time, 2) perform com-
parative analysis of various outcomes of different group
of patients, and 3) assess the likelihood of his patients
progressing to other disease states, to mention a few. 
CONCLUSION: The product derived from this research
project provides great promise to practitioners in private
practice to be active participants in outcomes research
and health economics.
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COMMUNITY PHARMACIST ASSESSMENT OF 
THE MOTIVATIONS FOR PROVIDING 
PHARMACEUTICAL CARE ACROSS
FOUR DOMAINS
Spruill WJ, Wade WE, Longe RL, Taylor TA, Burke SI
University of Georgia, Athens, GA, USA
OBJECTIVES: The provision of pharmaceutical care in
the community pharmacy setting has the potential to im-
prove patient outcomes while providing economic bene-
fits to the pharmacist. This study attempts to anony-
mously measure the value of and reasons that a group of
community pharmacists perform various pharmaceutical
care services for 10 disease states as measured in four
separate value domains. 
METHODS: Sixty community pharmacists were mailed
a questionnaire asking them to rank on a scale of 1 to 10
(1  strongly disagree; l0  strongly agree) reasons they
would provide pharmaceutical care to a patient with 1 of
10 diseases. Reasons were assessed in four separate do-
mains: financial, psychosocial, humanistic, and profes-
sional. Lastly, these reasons for providing pharmaceutical
care were evaluated by specific disease states. 
RESULTS: Thirty-eight pharmacists (63.3%) returned com-
pleted questionnaires. Strong agreement was seen across all
domains with an average of all domain scores of 7.48 
1.81. Individual domain scores ranked as psychosocial
7.97  1.72, professional 7.56  1.68, financial 7.24 
2.04, and humanistic 7.16  1.82. Rank order, by average
domain score, of individual disease states was asthma,
hypertension, diabetes, hypercholesterolemia, anticoagu-
